title: Pharmacokinetics and bioequivalence of 2 meloxicam oral dosage formulations in healthy adult horses.
abstract: Meloxicam, a non-steroidal anti-inflammatory drug, is approved for use in horses in several countries, but an equine formulation is not available in North America. However, meloxicam is being used in an extra-label manner in horses in Canada. The purpose of this study, therefore, was to assess the bioequivalence of an approved oral meloxicam suspension (Metacam 15 mg/mL for horses; Boehringer Ingelheim Vetmedica GmBH, Ingelheim, Germany) from the European Union with human meloxicam tablets (Meloxicam 15 mg tablets; TEVA Canada, Toronto, Ontario) compounded with molasses to improve palatability and administration. The geometric mean ratios (GMR test/reference) and the 90% confidence intervals of the pivotal pharmacokinetic parameters (area under the curve and maximum concentration) were within the defined limits of 80% to 125% generally accepted for products to be considered bioequivalent. Therefore, use of human meloxicam tablets compounded with molasses would be expected to produce a similar clinical response in horses as the approved oral product from the European Union.
authors.affiliation: Faculty of Veterinary Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, Alberta, Canada T2N 4Z6.
authors.forename: Melanie
authors.initials: M
authors.lastname: Vivancos
authors.affiliation: Faculty of Veterinary Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, Alberta, Canada T2N 4Z6.
authors.forename: Jessica
authors.initials: J
authors.lastname: Barker
authors.affiliation: Faculty of Veterinary Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, Alberta, Canada T2N 4Z6.
authors.forename: Sarah
authors.initials: S
authors.lastname: Engbers
authors.affiliation: Faculty of Veterinary Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, Alberta, Canada T2N 4Z6.
authors.forename: Carrie
authors.initials: C
authors.lastname: Fischer
authors.affiliation: Faculty of Veterinary Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, Alberta, Canada T2N 4Z6.
authors.forename: Jami
authors.initials: J
authors.lastname: Frederick
authors.affiliation: Faculty of Veterinary Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, Alberta, Canada T2N 4Z6.
authors.forename: Heather
authors.initials: H
authors.lastname: Friedt
authors.affiliation: Faculty of Veterinary Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, Alberta, Canada T2N 4Z6.
authors.forename: Joanna M
authors.initials: JM
authors.lastname: Rybicka
authors.affiliation: Faculty of Veterinary Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, Alberta, Canada T2N 4Z6.
authors.forename: Tereza
authors.initials: T
authors.lastname: Stastny
authors.affiliation: Faculty of Veterinary Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, Alberta, Canada T2N 4Z6.
authors.forename: Heidi
authors.initials: H
authors.lastname: Banse
authors.affiliation: Faculty of Veterinary Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, Alberta, Canada T2N 4Z6.
authors.forename: Alastair E
authors.initials: AE
authors.lastname: Cribb
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D019540:Area Under Curve; D018592:Cross-Over Studies; D004304:Dosage Forms; D005260:Female; D006207:Half-Life; D006736:Horses / Q000097:blood / Q000378:metabolism*; D008297:Male; D000077239:Meloxicam; D013810:Therapeutic Equivalency; D013843:Thiazines / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D013844:Thiazoles / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D004304:Dosage Forms; D013843:Thiazines; D013844:Thiazoles; D000077239:Meloxicam